Skip to main content
OpenTrials
Completed

NCT Number: NCT01142076

Xinju Xiaogao Prescription Study on Overweight

Xinju Xiaogao prescription and 10% of it in the treatment of adiposity (stagnation of QI causing phlegm retention)clinical study

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Charged by the three research centers in line with traditional Chinese medicine stagnation of QI causing phlegm retention 120 cases have diabetes were randomly divided into Chinese herbal compound Xinju Xiaogao prescription group and 10% of the prescription group.The treatment groups were compared 24-week step-down and regulation of body weight,waistline, blood lipids, blood sugar effect.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 18-60 years old
  • BMI≥28kg/m2,but<40kg/m2
  • Waistline≥85cm(male),≥80cm(female)
  • Pathoglycemia must fulfill one of those four condition:
  • IGT,7.8≤2hPG≤11.0mmol/,
  • diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤FBG≤12.2,and weight change under 4kg.
  • stagnation of QI causing phlegm retention
  • To sign informed consent.

Exclusion criteria

  • After 3-6 months simply controlling their diet and more exercise treatment, body weight weight loss ≥ 5%.
  • TG>4.5mmol/L.
  • Suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome.
  • There is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin.
  • Not suffered myocardial infarction in Past 3 months or unstable angina were confirmed.
  • Had been diagnosed as "post-surgical adhesions" .
  • There is a history of appetite or abuse of laxatives
  • Diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmHg .
  • Pregnancy, prepare to pregnant or lactating women prepare.
  • Allergies to Chinese medicine , allergic.
  • Recurrent gallstone or a history of kidney stones.
  • Mentally ill.
  • Cancer patients.
  • A history of gastrointestinal surgery to lose weight.
  • Receiving other clinical studies nearly 3 months.
  • Alcohol and / or psychoactive substances, drug abusers and addicts.
  • Taking other weight-reducing aid Close within one month

Treatment and study plan

Xinju Xiaogao Prescription

Drug

treatment group

Other names: Xinju Xiaogao decoction

Placebo

Drug

Therapeutic dose of 10%

Primary outcomes

  1. waistline

    Time frame: up to 24 weeks

Secondary outcomes

  1. Body Mass Index (BMI)

    Time frame: up to 24 weeks

Sponsors and collaborators

Lead sponsor

Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Other

Collaborators

  • China-Japan Friendship Hospital
  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Registry information

Official study title

Xinju Xiaogao Prescription and 10% of it in the Treatment of Adiposity (Stagnation of QI Causing Phlegm Retention)Clinical Study

Acronym: XJXG

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Jun 11, 2010
Registry last updated
Dec 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.